These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 16482722)

  • 1. Reader comments on the cost of cancer care.
    Toftbagen C
    Clin J Oncol Nurs; 2006 Feb; 10(1):15; author reply 15-6. PubMed ID: 16482722
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer?
    Cassidy J; Schmoll HJ; Van Cutsem E
    J Clin Oncol; 2008 May; 26(13):2226-7; author reply 2228. PubMed ID: 18445855
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost minimization comparison of oral UFT/leucovorin versus 5-fluorouracil/leucovorin as adjuvant therapy for colorectal cancer in Taiwan.
    Hsu TC; Wang CC
    J Comp Eff Res; 2019 Jan; 8(2):73-79. PubMed ID: 30560687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of costs for infusion versus bolus chemotherapy administration: analysis of five standard chemotherapy regimens in three common tumors--Part one. Model projections for cost based on charges.
    Lokich JJ; Moore CL; Anderson NR
    Cancer; 1996 Jul; 78(2):294-9. PubMed ID: 8674006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacoeconomic analysis of capecitabine versus 5-fluorouracil/leucovorin as adjuvant therapy for stage III colon cancer in Taiwan.
    Hsu TC; Chen HH; Yang MC; Wang HM; Chuang JH; Jao SW; Chiang HC; Wen CY; Tseng JH; Chen LT
    Value Health; 2011; 14(5):647-51. PubMed ID: 21839401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of mortality and costs associated with FOLFOX versus FOLFIRI in stage IV colorectal cancer.
    Nelson MA; Shetty S; Kulakodlu M; Harley C; Seal B
    J Med Econ; 2011; 14(2):179-86. PubMed ID: 21319948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacoeconomic benefits of capecitabine-based chemotherapy in metastatic colorectal cancer.
    Chu E; Cartwright TH
    J Clin Oncol; 2008 May; 26(13):2224-6; author reply 2228. PubMed ID: 18445854
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase III multicenter randomized clinical trial to evaluate the safety and efficacy of CoFactor/5-fluorouracil/bevacizumab versus leucovorin/5-fluorouracil/bevacizumab as initial treatment for metastatic colorectal carcinoma.
    Saif MW; Merritt J; Robbins J; Stewart J; Schupp J
    Clin Colorectal Cancer; 2006 Sep; 6(3):229-34. PubMed ID: 17026795
    [No Abstract]   [Full Text] [Related]  

  • 9. Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer.
    Whyte S; Pandor A; Stevenson M; Rees A
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):47-53. PubMed ID: 21047491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxaliplatin (Eloxatin) for advanced colon cancer.
    Med Lett Drugs Ther; 2003 Jan; 45(1148):7-8. PubMed ID: 12571541
    [No Abstract]   [Full Text] [Related]  

  • 11. Economic impact of simplified de Gramont regimen in first-line therapy in metastatic colorectal cancer.
    Limat S; Bracco-Nolin CH; Legat-Fagnoni C; Chaigneau L; Stein U; Huchet B; Pivot X; Woronoff-Lemsi MC
    Eur J Health Econ; 2006 Jun; 7(2):107-13. PubMed ID: 16474968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The price tag on progress--chemotherapy for colorectal cancer.
    Schrag D
    N Engl J Med; 2004 Jul; 351(4):317-9. PubMed ID: 15269308
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost-minimisation analysis in first-line treatment of metastatic colorectal cancer in France: XELOX versus FOLFOX-6.
    Perrocheau G; Bennouna J; Ducreux M; Hebbar M; Ychou M; Lledo G; Conroy T; Dominguez S; Faroux R; Florentin V; Douillard JY
    Oncology; 2010; 79(3-4):174-80. PubMed ID: 21358204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-minimization analysis of sequence changes between FOLFIRI and FOLFOX6 therapy for advanced colorectal cancer in Japan.
    Miyazaki Y; Harada T; Akase T; Arakawa I; Inoue T
    Clin Ther; 2009; 31 Pt 2():2433-41. PubMed ID: 20110051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Innovative chemotherapies for stage III colon cancer: a cost-effectiveness study.
    Koperna T; Semmler D
    Hepatogastroenterology; 2003; 50(54):1903-9. PubMed ID: 14696430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan.
    Shiroiwa T; Fukuda T; Tsutani K
    Clin Ther; 2007 Oct; 29(10):2256-67. PubMed ID: 18042483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of costs for infusion versus bolus chemotherapy administration--Part two. Use of charges versus reimbursement for cost basis.
    Lokich JJ; Moore CL; Anderson NR
    Cancer; 1996 Jul; 78(2):300-3. PubMed ID: 8674007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma.
    Hillner BE; Schrag D; Sargent DJ; Fuchs CS; Goldberg RM
    Cancer; 2005 Nov; 104(9):1871-84. PubMed ID: 16177989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and economic evaluation of first-line therapy with FOLFIRI or modified FOLFOX6 for metastatic colorectal cancer.
    Ajima H; Ogata H; Fujita K; Miwa K; Sunakawa Y; Mizuno K; Ishida H; Yamashita K; Nakayama H; Kawara K; Takahashi H; Sasaki Y
    Jpn J Clin Oncol; 2010 Jul; 40(7):634-8. PubMed ID: 20587616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of 10 min infusion of bevacizumab in combination with 5FU-based chemotherapy in non-selected metastatic colorectal cancer patients.
    Coriat R; Mir O; Chaussade S; Goldwasser F
    Dig Liver Dis; 2011 Mar; 43(3):248-9. PubMed ID: 21145299
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.